TS Trillion Valuation
Is A317240 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A317240 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A317240's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A317240's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A317240?
Other financial metrics that can be useful for relative valuation.
What is A317240's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩30.76b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 35.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A317240's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.8x | ||
A900120 CXI Healthcare Technology Group | 0.5x | n/a | ₩31.7b |
A014100 Medience | 0.6x | n/a | ₩38.3b |
A065170 BL Pharmtech | 1.8x | n/a | ₩44.0b |
A353190 Hurum | 0.5x | n/a | ₩40.1b |
A317240 TS Trillion | 0.8x | n/a | ₩30.8b |
Price-To-Sales vs Peers: A317240 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does A317240's PE Ratio compare vs other companies in the KR Personal Products Industry?
Price-To-Sales vs Industry: A317240 is good value based on its Price-To-Sales Ratio (0.8x) compared to the KR Personal Products industry average (1.2x).
Price to Sales Ratio vs Fair Ratio
What is A317240's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.8x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A317240's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.